On September 1, 2026, Alumis Inc. announced that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) failed to meet primary and secondary endpoints in the overall population of 408 patients. The failure was attributed to a higher-than-expected proportion of IFNGS-low patients, which drove high placebo response rates. However, robust clinical responses were observed in the prespecified IFNGS-high subgroup across BICLA, SRI-4, and CLASI-50 endpoints. Pharmacodynamic data confirmed dose-dependent interferon-pathway target engagement with no new safety signals. Alumis plans to engage regulators regarding Phase 3 development for this specific subgroup while remaining on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Alumis Inc. is a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases.

Alumis Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $142.2 million compared to net income of $59.3 million in the prior year period. The company held cash and marketable securities of $502.3 million as of June 30, 2026, which management expects will fund operations into the fourth quarter of 2027. Operating expenses included a $41.8 million impairment loss related to the lonigutamab program following a decision to explore strategic alternatives for the asset. R&D expenses decreased to $85.3 million from $108.8 million, while G&A expenses fell to $23.4 million from $34.5 million. The company remains on track to submit an NDA for envudeucitinib in plaque psoriasis in Q4 2026 and anticipates Phase 2b LUMUS data for SLE in Q3 2026. Alumis Inc. is a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases.